mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration		Intramuscular

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). [4]

Clinical Trial

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[5] As of September 2022, the trial is in Phase 2 [6]

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature. [4]

References

  1. ↑ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
  2. ↑ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  3. ↑ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
  4. 1 2 "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 1 August 2023.
  5. ↑ Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R (December 2023). "Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults". Human Vaccines & Immunotherapeutics. 19 (1): 2190690. doi:10.1080/21645515.2023.2190690. PMC 10128428. PMID 37074202.
  6. ↑ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.org. Retrieved 29 April 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.